PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026Nature Communications0 citationsOpen Access

A biomimetic nanodisc system selectively activates type I interferons by nonclassical STING pathway for cancer immunotherapy

QMQianwen MuHDHaolan DengSLShuo Li

Key Points

  • The research aims to develop a nanodisc system that activates the type I interferon signaling pathway through the STING pathway, bypassing traditional cellular pathways.
  • Developed a cell membrane-derived nanodisc system (ND-cGAMP-HP) to present activated STING proteins.
  • Utilized biological self-assembly techniques to create the nanodisc system.
  • Introduced STING protein directly to tumor cells, avoiding translocation through ER and Golgi.
  • Examined immune responses and microenvironment remodeling.
  • ND-cGAMP-HP selectively activated the IFN-I signaling pathway without triggering the NF-κB pathway.
  • Triggered strong cellular immune responses in tumor cells.
  • Promoted differentiation of TCF1+ stem cell-like T cells, enhancing immune memory.

Abstract

The epigenetic silencing or remarkably diminished expression of STING in cancer cells, along with the structural and functional impairment of the endoplasmic reticulum (ER) and Golgi apparatus, represents a unique mechanism of tumor immune escape and poses an important challenge for STING-targeted therapies. Here, we develop a cell membrane-derived nanodisc system (ND-cGAMP-HP; HP, heparin), which is capable of presenting activated STING proteins in their native form by means of cell membrane-directed display and biological self-assembly techniques. It can directly introduce activated STING protein to tumor cells and circumvent the translocation process between the ER and Golgi apparatus, selectively activating the IFN-I signaling pathway without initiating the inflammation-related pathway NF-κB. ND-cGAMP-HP triggers potent cellular immune responses and remodels the tumor immune microenvironment. Moreover, it augments immune memory by promoting the differentiation of TCF1+ stem cell-like T cells. We thus manifest a strategy based on STING therapy that does not depend on the ER and Golgi apparatus pathways to activate the IFN-I pathway, for cancer immunotherapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mu et al. (2026) studied this question.

synapsesocial.com/papers/69cf5de95a333a821460bed4https://doi.org/10.1038/s41467-026-71363-6
Ask AI
Helpful
Bookmark
Share
View Full Paper